Evidence map›Paper›PMID 21766436›Full record

ArticleAmerican journal of medical genetics. Part C, Seminars in medical genetics2011

We don't know what we don't study: the case for research on medication effects in pregnancy.

Melissa A Parisi, Catherine Y Spong, Anne Zajicek, Alan E Guttmacher

Open access · greenAbstract read
In one paragraph

Article in American journal of medical genetics. Part C, Seminars in medical genetics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
6.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 52 citations in OpenAlex.

  1. Article
  2. Maternal medication use in pregnancy and offspring ASD risk: A prescription-wide, target-informed study.European psychiatry : the journal of the Association of European Psychiatrists · 2025
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Reply: To PMID 24881821.American journal of obstetrics and gynecology · 2015
    Article
  16. Article
  17. Prescription drug use during and immediately before pregnancy in Hawai'i—findings from the Hawai'i Pregnancy Risk Assessment Monitoring System, 2009-2011.Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health · 2014
    Article
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Melissa A ParisiIntellectual and Developmental Disabilities Branch, Center for Developmental Biology and Perinatal Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, 6100 Executive Boulevard, Bethesda, MD 20892-7510, USA. parisima@mail.nih.gov
Catherine Y Spong
Anne Zajicek
Alan E Guttmacher
Eunice Kennedy Shriver National Institute of Child Health and Human Development · US

Funding

Intramural NIH HHS Z99 HD999999
6 · The paper itself

Abstract

This Commentary addresses issues related to exposures to teratogens and makes the case for increased research into the safety of medication usage during pregnancy for mothers and fetuses. Not only are medications commonly used during pregnancy, but evidence points to an increasing prevalence and number of drug exposures experienced by the embryo or fetus, particularly during the critical first trimester of pregnancy. Although the first trimester represents a particularly vulnerable period of organogenesis, exposures during other gestational time periods may also be associated with deleterious outcomes. In addition to the changing (and in many cases unknown) risks to a developing fetus, other challenges to studying medication exposures and their effects during pregnancy include the dramatic changes in physiology that occur in pregnant women and the ethical dilemmas posed by including this vulnerable population in randomized controlled trials of safety and efficacy. However, without adequate knowledge of the pharmacokinetics, pharmacodynamics, efficacy, and safety of medication use in pregnancy, women may be under-dosed to minimize exposure or not treated at all, resulting in inadequate treatment and potential harm to the mother and her baby. The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is undertaking studies on medications and teratogenic exposures during pregnancy, including alcohol, maternal diabetes, oral hypoglycemic agents, and antiviral medications, through several of its research networks. Although this is a start, there is a critical need for further research on medications used during pregnancy, especially their effects on both the mother and her developing child.

Indexed as

Drug-Related Side Effects and Adverse ReactionsTeratogensAbnormalities, Drug-InducedFemaleHumansPregnancyPregnancy ComplicationsPregnancy OutcomePrenatal Exposure Delayed EffectsRisk AssessmentTeratogens

Identifiers

PMID21766436
PMCPMC3140632
OpenAlexW2017046689

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.